Once-daily versus Twice-daily Levobunolol (0.5%) Therapy: A Crossover Study

Robert J. Derick, Alan L. Robin, James Tielsch, Jeffrey L. Wexler, Elaine P. Kelley, Jack F. Stoecker, Gary D. Novack, Anne L. Coleman

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (10P). Modified diurnal curves were performed at four times for each study arm: baseline, day 1, day 14, and day 28. The mean diurnal corrected decrease in 10P from baseline ranged from 16% ± 11 % to 22% ± 9% when the subjects were treated twice daily, and from 14% ± 10% to 18% ± 8% when the same subjects were treated once daily. At day 1, patients had a significantly greater 101? lowering after twice-daily therapy than after once-daily therapy (P < 0.05). At 14 and 28 days, there was no clinically significant difference between the two treatment regimens. The results of our crossover study suggest that once-daily treatment with levobunolol (0.5%) is as effective as twice-daily treatment.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
Issue number3
StatePublished - 1992

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Once-daily versus Twice-daily Levobunolol (0.5%) Therapy: A Crossover Study'. Together they form a unique fingerprint.

Cite this